No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block

Morten Bækgaard Thomsen; J D M Beekman; N J M Attevelt; A Takahara; A Sugiyama; K Chiba; M A Vos

doi:10.1038/sj.bjp.0706900

No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block

Morten Bækgaard Thomsen, J D M Beekman, N J M Attevelt, A Takahara, A Sugiyama, K Chiba, M A Vos

Physiology of circulation, kidney and lung

57 Citationer (Scopus)

Abstract

The therapeutically available quinolone antibiotic moxifloxacin has been used as a positive control for prolonging the QT interval in both clinical and non-clinical studies designed to assess the potential of new drugs to delay cardiac repolarization. Despite moxifloxacin prolonging QT, it has not been shown to cause torsades de pointes arrhythmias (TdP). Azithromycin is a macrolide antibiotic that has rarely been associated, clinically, with cases of proarrhythmia. As there is a lack of clinical data available, the cardiac safety of these drugs was assessed in a TdP-susceptible animal model by evaluating their repolarization and proarrhythmia effects.

Originalsprog	Engelsk
Tidsskrift	British Journal of Pharmacology
Vol/bind	149
Udgave nummer	8
Sider (fra-til)	1039-48
Antal sider	10
ISSN	0007-1188
DOI	https://doi.org/10.1038/sj.bjp.0706900
Status	Udgivet - dec. 2006

Adgang til dokumentet

10.1038/sj.bjp.0706900

Citationsformater

@article{289cdbad381049d796f6b6cedc7816ae,

title = "No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block",

abstract = "The therapeutically available quinolone antibiotic moxifloxacin has been used as a positive control for prolonging the QT interval in both clinical and non-clinical studies designed to assess the potential of new drugs to delay cardiac repolarization. Despite moxifloxacin prolonging QT, it has not been shown to cause torsades de pointes arrhythmias (TdP). Azithromycin is a macrolide antibiotic that has rarely been associated, clinically, with cases of proarrhythmia. As there is a lack of clinical data available, the cardiac safety of these drugs was assessed in a TdP-susceptible animal model by evaluating their repolarization and proarrhythmia effects.",

keywords = "Anesthesia, Animals, Anti-Arrhythmia Agents, Anti-Bacterial Agents, Arrhythmias, Cardiac, Aza Compounds, Azithromycin, Dogs, Dose-Response Relationship, Drug, Electric Stimulation, Electroencephalography, Electrophysiology, Heart Block, Heart Rate, Long QT Syndrome, Phenethylamines, Quinolines, Sulfonamides, Torsades de Pointes",

author = "Thomsen, {Morten B{\ae}kgaard} and Beekman, {J D M} and Attevelt, {N J M} and A Takahara and A Sugiyama and K Chiba and Vos, {M A}",

year = "2006",

month = dec,

doi = "10.1038/sj.bjp.0706900",

language = "English",

volume = "149",

pages = "1039--48",

journal = "British Journal of Pharmacology",

issn = "0007-1188",

publisher = "Wiley",

number = "8",

}

TY - JOUR

T1 - No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block

AU - Thomsen, Morten Bækgaard

AU - Beekman, J D M

AU - Attevelt, N J M

AU - Takahara, A

AU - Sugiyama, A

AU - Chiba, K

AU - Vos, M A

PY - 2006/12

Y1 - 2006/12

N2 - The therapeutically available quinolone antibiotic moxifloxacin has been used as a positive control for prolonging the QT interval in both clinical and non-clinical studies designed to assess the potential of new drugs to delay cardiac repolarization. Despite moxifloxacin prolonging QT, it has not been shown to cause torsades de pointes arrhythmias (TdP). Azithromycin is a macrolide antibiotic that has rarely been associated, clinically, with cases of proarrhythmia. As there is a lack of clinical data available, the cardiac safety of these drugs was assessed in a TdP-susceptible animal model by evaluating their repolarization and proarrhythmia effects.

AB - The therapeutically available quinolone antibiotic moxifloxacin has been used as a positive control for prolonging the QT interval in both clinical and non-clinical studies designed to assess the potential of new drugs to delay cardiac repolarization. Despite moxifloxacin prolonging QT, it has not been shown to cause torsades de pointes arrhythmias (TdP). Azithromycin is a macrolide antibiotic that has rarely been associated, clinically, with cases of proarrhythmia. As there is a lack of clinical data available, the cardiac safety of these drugs was assessed in a TdP-susceptible animal model by evaluating their repolarization and proarrhythmia effects.

KW - Anesthesia

KW - Animals

KW - Anti-Arrhythmia Agents

KW - Anti-Bacterial Agents

KW - Arrhythmias, Cardiac

KW - Aza Compounds

KW - Azithromycin

KW - Dogs

KW - Dose-Response Relationship, Drug

KW - Electric Stimulation

KW - Electroencephalography

KW - Electrophysiology

KW - Heart Block

KW - Heart Rate

KW - Long QT Syndrome

KW - Phenethylamines

KW - Quinolines

KW - Sulfonamides

KW - Torsades de Pointes

U2 - 10.1038/sj.bjp.0706900

DO - 10.1038/sj.bjp.0706900

M3 - Journal article

C2 - 17088870

SN - 0007-1188

VL - 149

SP - 1039

EP - 1048

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

IS - 8

ER -

No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater